Study of Perifosine + Capecitabine for Colon Cancer Patients

Colon Cancer Clinical Trial

Official title:

A Phase I Study of Perifosine + Capecitabine for Patients With Advanced Colon Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01048580
• Other study ID #: Perifosine 141
• Status: Completed
• Phase: Phase 1
• Start date: October 2009
• Est. completion date: October 2011

Study information

• Verified date: November 2011
• Source: AEterna Zentaris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I study of Perifosine + Capecitabine for patients with advanced colon cancer.

Description:

This study is a Phase I trial. A total of 3 ‐ 9 patients will be enrolled. Three patients will initially be enrolled. There will be no dose escalation in this study as only one dose for perifosine (50 mg) in combination with one dose of capecitabine (1000 mg/m2 BID) will be evaluated. The maximum tolerated dose (MTD) is defined in which fewer than 33% of patients experienced DLT attributable to the study drug(s), when at least six patients have been treated at that dose and are evaluable for toxicity. Pharmacokinetic (PK) data will also be evaluated from all enrolled patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: October 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with 3rd line or > metastatic colon cancer

• Patients must have received or not be candidates for regimens containing 5- FU, oxaliplatin, irinotecan, bevacizumab, and cetuximab or panitumumab

• No prior exposure to perifosine

• Adequate bone marrow, liver, and renal function

• Patients must have at least one measurable lesion

• Patients must agree to have extra blood drawn for PK analyses

Exclusion Criteria:

• Patients with prior exposure to perifosine.

• Patients receiving any other investigational agents or devices.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).

• Patients with known dipyrimidine dehydrogenase (DPD) deficiency or prior severe reaction to 5-FU.

• Patients with known central nervous system CNS metastases.

• Patients with known HIV, Hepatitis B, or Hepatitis C seropositivity.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection and psychiatric illness/social situations that would limit compliance with study requirements.

• Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment), or New York Heart Association class II-IV congestive heart failure.

• Female patients who are pregnant or lactating are ineligible.

Related Conditions & MeSH terms

• Colon Cancer
• Colonic Neoplasms

Intervention

Drug:
• Perifosine
Perifosine 50 mg orally once a day (Days 1-21)
• Capecitabine
Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
AEterna Zentaris	SCRI Development Innovations, LLC

References & Publications (1)

Journal of Oncology, 2010 ASCO Annual Meeting Abstracts. Vol. 28, No. 15_suppl (May 20Supplement), 2010:e14086

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of the combination of perifosine and capecitabine (i.e., dose limiting toxicity)	The maximum tolerated dose (MTD) is defined in which fewer than 33% of patients experienced dose limiting toxicity (DLT) attributable to the study drug(s), when at least six patients were treated at that dose and are evaluable for toxicity. A DLT will be defined as any of the following deemed to be related to study drug(s): Grade 3 non-hematologic toxicity except alopecia not reversible to Grade 2 or less within 96 hours; Any Grade 4 toxicity DLT will be based on the first cycle of treatment (first 21 days). Toxicity will be graded according to the NCI CTCAE version 3.0. To be evaluable for toxicity, a patient must receive at least 1 complete course of treatment or have experienced DLT.	Every 3 weeks after dosing
Secondary	Best overall response	The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).; Response Evaluation Criteria in solid tumors (RECIST): Measurable disease is defined as the presence of at least one measurable lesion. Measurable lesions are lesions that can be accurately measured in at least one dimension and fit one of the following criteria: Longest diameter = 20 mm using conventional techniques, or; = 10 mm with spiral CT scan.	Every 3 cycles after dosing (length of one cycle is 21 days)
Secondary	Time to progression	This is the interval from the initiation of treatment to the time of documented, objective progression using the same methods of evaluation that were used at baseline.; In order for a patient to be regarded as having progressive disease, the following criteria must be met: The site of disease must have been evaluated either at baseline or while receiving study medication. Both evaluations must use the same methodology.; PET scan results will not be used as evidence of either progression or response..	Every 3 cycles after dosing (length of one cycle is 21 days)
Secondary	Pharmacokinetic (PK) data for the combination of perifosine and capecitabine	PK data will also be evaluated from all enrolled patients. PK analyses will present peak plasma concentrations (Cmax) as well as Area under the plasma concentration verus time curve (AUC).	Up to cyle 5 no pharmacokinetic samples were obtained. Cycle 1/Day 11 until Cycle 4/Day 11: pharmacokinetic samples obtained 0.5, 1, 2, 4, 6 and 8 hours after dosing